Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

60.37 UNCHANGED

Delayed Quote Updated: 3:59 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

38 39 Next >

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections ↗

September 16, 2024

The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first twice-a-year subcutaneous injection option for both forms of the disease.

Via Benzinga

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

September 13, 2024

From Genentech

Via Business Wire

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review ↗

September 13, 2024

The major indexes reclaimed key levels and many leaders flashed buy signals.

Via Investor's Business Daily

Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735 ↗

September 13, 2024

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right track.

Via The Motley Fool

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

September 12, 2024

From Genentech

Via Business Wire

Why Roche Holdings Stock Withered on Wednesday ↗

September 11, 2024

The company had a dispiriting update to offer about an investigational drug.

Via The Motley Fool

Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease ↗

September 09, 2024

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in...

Via Benzinga

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗

September 09, 2024

HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant...

Via Benzinga

The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗

August 29, 2024

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Via Investor's Business Daily

Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales ↗

August 29, 2024

BioNTech and Moderna are advancing personalized cancer vaccines using mRNA technology. Despite promising early results, these innovative treatments face challenges in cost, scalability, and...

Via Benzinga

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug ↗

August 27, 2024

The single-dose vials will also increase supply, the drug giant says.

Via Investor's Business Daily

Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain ↗

August 26, 2024

Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing...

Via Benzinga

Biotech Bull Market: 3 Ways To Play It ↗

August 20, 2024

Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.

Via Talk Markets

Topics Economy

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter ↗

August 19, 2024

The company reported a surprise profit in the second quarter, vs. expectations for losses.

Via Investor's Business Daily

Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years ↗

August 18, 2024

Should Novo Nordisk and Eli Lilly investors be worried about Roche?

Via The Motley Fool

Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market ↗

August 16, 2024

Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while...

Via Benzinga

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? ↗

August 15, 2024

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...

Via Benzinga

Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer) ↗

August 15, 2024

There are a number of pharmaceutical companies looking to make waves in the weight loss market.

Via The Motley Fool

Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome ↗

August 13, 2024

Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...

Via Benzinga

Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects ↗

August 08, 2024

Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased...

Via Benzinga

Here's Why Eli Lilly Stock Dropped 12% Last Month ↗

August 08, 2024

News from a competitor gave investors an unwelcome dose of reality.

Via The Motley Fool

Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions ↗

August 07, 2024

Roche considers divesting Flatiron Health, acquired for $1.9 billion in 2018, highlighting the challenges big pharma faces with start-up investments. Flatiron's data aids Roche's oncology R&D despite...

Via Benzinga

Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus ↗

August 05, 2024

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...

Via Benzinga

Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. ↗

August 02, 2024

Via The Motley Fool

Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It? ↗

July 29, 2024

Roche's latest breakthrough could be a game changer, but it's still too early to say.

Via The Motley Fool

Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On ↗

July 24, 2024

Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.

Via Benzinga

Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch? ↗

July 23, 2024

Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road.

Via The Motley Fool

Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier ↗

July 22, 2024

Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...

Via Benzinga

This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It? ↗

July 22, 2024

This company hasn't made its debut on the weight-loss market yet, but it may.

Via The Motley Fool

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.